Tag Archives: Gilead Sciences

Needham Maintains Their Hold Rating on Gilead Sciences (GILD)

In a report released today, Joseph Stringer from Needham maintained a Hold rating on Gilead Sciences (GILD – Research Report). The company’s shares closed last Thursday at $63.84. According to TipRanks.com, Stringer is currently ranked with 0 stars on a

Gilead Sciences (GILD) Receives a Hold from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Gilead Sciences (GILD – Research Report) on October 28. The company’s shares closed last Monday at $60.83, close to its 52-week low of $57.04. According to TipRanks.com, Kasimov is a

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (NASDAQ: GILD) and Voyager Therapeutics (NASDAQ: VYGR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD – Research Report) and Voyager Therapeutics (VYGR – Research Report). Gilead Sciences (GILD) Raymond James analyst Steven Seedhouse maintained a

J.P. Morgan Maintains Their Hold Rating on Gilead Sciences (GILD)

In a report issued on July 30, Cory Kasimov from J.P. Morgan maintained a Hold rating on Gilead Sciences (GILD – Research Report). The company’s shares closed last Thursday at $68.81. According to TipRanks.com, Kasimov is a 5-star analyst with

Gilead Sciences (GILD) Gets a Hold Rating from Maxim Group

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Gilead Sciences (GILD – Research Report). The company’s shares closed last Friday at $69.53. According to TipRanks.com, McCarthy is a top 100 analyst with an

Gilead Sciences (GILD) Gets a Hold Rating from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Gilead Sciences (GILD – Research Report) on July 21 and set a price target of $85.00. The company’s shares closed last Monday at $74.54. According to TipRanks.com, Kasimov is a